亞太研究抗體試劑市場規模、份額及趨勢分析報告－產業趨勢及2032年預測

亞太研究抗體試劑市場分析

亞太研究抗體試劑市場是生命科學和生物技術產業中一個快速成長的領域。抗體試劑是研究應用中的重要工具，包括診斷、藥物開發、疾病了解和生物標記發現。由於個人化醫療需求的不斷增長、基因組學和蛋白​​質組學的進步以及癌症、糖尿病和自體免疫疾病等慢性疾病的盛行率不斷上升，市場經歷了顯著增長。

亞太研究抗體試劑市場規模

2024 年亞太研究抗體試劑市場規模為 20.8 億美元，預計到 2032 年將達到 36.5 億美元，在 2025 年至 2032 年的預測期內複合年增長率為 7.5%。

除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括進出口分析、生產能力概覽、生產消費分析、價格趨勢分析、氣候變遷情景、供應鏈分析、價值鏈分析、原材料/消耗品概覽、供應商選擇標準、PESTLE 分析、波特分析和監管框架。

亞太研究抗體試劑市場趨勢

“個人化醫療和標靶治療的需求日益增長”

亞太研究抗體試劑市場的一個重要趨勢是對個人化醫療和標靶治療的需求不斷增加，這推動了抗體開發的創新。隨著研究人員和製藥公司專注於根據個別患者情況開發客製化治療方法，對能夠準確針對與各種疾病相關的特定生物標記的高特異性和親和力抗體的需求日益增加。單株抗體生產、重組 DNA 技術和 CRISPR 等技術的進步進一步推動了這一趨勢，從而帶來了可提高診斷和治療應用有效性的新型抗體試劑的推出。此外，生物庫和精準研究計畫的成長促進了可用試劑種類的擴大，支持了市場向更專業、更有效的研究工具的發展。

報告範圍和亞太研究抗體試劑市場細分

Asia-Pacific Research Antibodies Reagents Market Definition

The Asia-Pacific research antibodies reagents market refers to the commercial sector involving the production, distribution, and utilization of antibodies and related reagents used in research applications across various fields, including biotechnology, pharmaceuticals, and academic research. This market encompasses a wide range of products, including monoclonal and polyclonal antibodies, secondary antibodies, antibody fragments, and conjugated antibodies, which are essential tools for a variety of applications such as immunohistochemistry, Western blotting, Enzyme-Linked Immunosorbent Assays (ELISA), and flow cytometry. The market is driven by the growing need for innovative research tools to support drug discovery, disease diagnosis, and personalized medicine, as well as advancements in antibody technologies and increasing funding for research in life sciences.                   

Asia-Pacific Research Antibodies Reagents Market Dynamics

Drivers  

• Increase in Technological Advancements    

Technological advancements play a crucial role in driving the Asia-Pacific research antibodies reagents market by enabling the development of more specific, efficient, and diverse antibody products. Innovations such as monoclonal antibody production processes, phage display technology, and recombinant DNA technologies have significantly improved the ability to produce high-quality antibodies with enhanced specificity and affinity. These technologies allow researchers to create antibodies that are tailored to specific targets, which is essential in various applications, including drug development, diagnostics, and basic research. The continuous evolution of high-throughput screening techniques and the integration of bioinformatics tools further accelerate the discovery and validation of novel antibodies, leading to a broader range of reagents available on the market and meeting the diverse needs of the scientific community.

For instance,

• In November 2024, according to an article published in the National Library of Medicine, breakthroughs in genetic engineering have enabled the production of humanized antibodies and the advances in Fc engineering, thereby increasing therapeutic efficacy. The discovery of immune checkpoints and cytokines revolutionized the treatment of cancer and autoimmune diseases
• 2021年2月，根據美國國家醫學圖書館發表的一篇文章，目前，超過500種抗體處於早期研究階段，而超過50種mAb處於臨床開發的最後階段，其中大多數針對對抗癌症和自體免疫或發炎性疾病，例如黑色素瘤、狼瘡和類風濕性關節炎

神經退化性疾病盛行率不斷上升             

阿茲海默症、帕金森氏症和肌萎縮側索硬化症（ALS）等神經退化性疾病的盛行率不斷上升，大大推動了全球市場對研究抗體試劑的需求。由於人口老化和生活方式改變等因素導致這些疾病的發病率上升，迫切需要進行持續研究以揭示其潛在機制、確定早期診斷的生物標記並開發有效的治療方法。抗體在該研究中發揮著至關重要的作用，因為它們是研究神經退化性疾病病理過程的重要工具。人們對理解和對抗神經退化性疾病的日益關注推動了對開發與這些疾病相關的蛋白質的特定抗體的投資，從而擴大了研究抗體試劑的市場。

例如，

• 2021年2月，根據美國國家醫學圖書館發表的一篇文章，神經系統疾病是全球身體和認知障礙的主要原因，目前影響全球約15%的人口。過去 30 年來，絕對患者數大幅增加。此外，預計未來二十年慢性神經退化性疾病的負擔將至少翻倍

此外，政府機構和私人組織為神經科學研究分配的資金和資源增加，為抗體試劑市場的成長創造了有利的環境。隨著製藥和生物技術公司加強開發新療法，包括用於治療神經退化性疾病的單株抗體和其他生物製劑，對支持臨床前和臨床研究的高品質研究抗體和試劑的需求正在上升。這一趨勢為專門從事抗體生產和相關試劑的公司帶來了機會，使他們能夠增強產品供應並為神經退化性疾病治療的進步做出貢獻，最終使患者和醫療保健系統受益。

機會

• 個人化醫療需求不斷成長

個人化醫療需求的不斷成長為市場帶來了巨大的機會。個人化醫療是根據個人的基因組成、生活方式和環境來制定治療方案，由於其具有改善患者治療效果和減少不良反應的潛力而獲得了發展動力。這一趨勢推動了對先進診斷工具和生物標記發現的需求，而這些工具和生物標記嚴重依賴抗體和試劑。

抗體在個人化醫療中發揮著至關重要的作用，特別是在識別和針對與疾病相關的特定生物標記方面。單株抗體和多株抗體對於開發精準治療和伴隨診斷至關重要，而精準治療和伴隨診斷對於個人化治療計畫至關重要。例如，在癌症研究中，抗體可以針對特定的腫瘤抗原，因此可以開發出比傳統治療更有效、更毒性的治療方法。同樣，在自體免疫疾病中，抗體可用於識別指導治療決策的特定免疫標記。

隨著越來越多的研究機構和製藥公司專注於開發個人化療法，對高品質抗體和試劑的需求日益增加，以幫助發現和驗證生物標記。這些工具對於創建診斷測試以確定最適合個別患者的治療方法至關重要，從而改善治療效果。

• 自體免疫疾病和傳染病研究的成長

隨著生物技術的不斷進步和全球傳染病負擔的不斷增加，對精確診斷工具和標靶治療的需求也越來越大。由於抗體和試劑在診斷和治療多種傳染病（例如 COVID-19、結核病、愛滋病毒以及伊波拉和猴痘等新發病原體）中發揮關鍵作用，因此該領域對抗體和試劑的需求特別高。

對於傳染病來說，抗體對於開發檢測特定病原體或其生物標記的快速診斷測試至關重要。單株抗體對於開發針對致病微生物的特定抗原的各種傳染病的檢測和治療至關重要。此外，抗體在疫苗研發中發揮關鍵作用，有助於在病原體造成傷害之前識別並消滅它們。隨著對大流行病防範的日益重視，基於抗體的試劑對於快速識別和分離傳染源至關重要。

當免疫系統攻擊人體自體細胞時就會發生自體免疫疾病，對此類疾病的研究也越來越受到關注。人們越來越多地使用專門針對參與疾病過程的免疫細胞的抗體來研究類風濕性關節炎、紅斑性狼瘡和多發性硬化症等疾病。這些發展對於開發更有效、毒性更小的治療方法至關重要，為患者提供新的治療選擇。人們對免疫療法（利用抗體調節免疫反應）的興趣日益濃厚，也擴大了該領域的研究。

限制/挑戰

• 替代技術的使用日益增多    

替代療法的日益普及為全球研究抗體試劑市場帶來了重大挑戰。隨著研究轉向基因療法、細胞療法和基於 RNA 的治療等新興治療方式，對傳統基於抗體的方法的依賴可能會減少。這種轉變可能會導致對傳統研究抗體的需求波動，因為資金和研究重點越來越傾向於這些創新的替代方案而不是既定的方法，這可能會導致抗體試劑供應商的市場萎縮。此外，替代療法的快速發展可能會超越抗體製造商的適應能力，從而造成研究人員的需求與現有產品之間的差距。

例如，

• 2024 年 5 月，根據《血友病基因治療的最新進展：展望》一文，基因治療被認為是最有前景的方法，因為它可以克服與傳統治療相關的問題
• 2020 年 4 月，據美國政府問責局稱，科學家正在使用 CRISPR/CAS9 技術開發診斷測試，可以快速識別鐮狀細胞性貧血和某些類型癌症等疾病。它們透過改變昆蟲或其他可傳播疾病的生物體的特性來幫助控制某些疾病

此外，新療法的複雜性和特異性可能會進一步挑戰抗體市場。當研究人員探索需要高度專業化或工程化抗體的新方法時，尋找合適的試劑來滿足這些新需求可能會遇到困難。這給製造商帶來了壓力，迫使他們投資研發這些先進療法的新型抗體和試劑。此類投資可能不會立即產生回報，從而給傳統上依賴標準研究抗體銷售的公司帶來財務壓力。因此，對替代療法日益增長的需求可能迫使抗體供應商要么使其產品多樣化，要么在不斷發展的治療環境中面臨過時的風險。  

• 需要與抗體試劑處理相關的專業知識 

The need for specialized expertise in the handling of antibody reagents presents a significant challenge for the research antibodies reagents market. Antibodies are complex molecules that require meticulous handling, storage, and application to maintain their stability and functionality. Researchers must be well-versed in various protocols, including dilution, labelling, and conjugation techniques, to ensure that they achieve reliable and reproducible results in their experiments. This necessity for expertise can create barriers for organizations, particularly smaller labs or those in developing regions, which may lack access to adequately trained personnel or resources. As a consequence, the effective utilization of antibody reagents may be compromised, leading to suboptimal research outcomes and potential wastage of costly materials, ultimately challenging the overall growth of the market.

For instance,

• In August 2024, according to an article published by MBL International Corporation, Proper storage and handling of antibody reagents are crucial for maintaining their effectiveness over time. Antibodies degrade or lose activity if not stored under optimal conditions
• In May 2024, according to an article published by AByntek Biopharma S.L., The development of a successful diagnostic test or assay requires a secure supply chain of high-quality reagents. Recombinant antibody technology enables the production of highly reliable antibodies adapted to your specific assay, providing superior performance throughout the lifespan of your diagnosis

Moreover, the evolving landscape of antibody technologies, including advancements in humanization, engineering, and validation, necessitates continuous education and training for researchers. Moreover, as regulatory standards become increasingly stringent for antibody-based diagnostics and therapeutics, researchers must ensure compliance, which adds another layer of complexity in both research and applications. This reliance on expertise may limit the scalability of the market, as it could result in unequal access to advanced antibody reagents, stifling innovation and collaborations among various research institutions and industries. Consequently, the need for specialized knowledge in handling antibody reagents and constrains market growth and restricts the potential for new discoveries in biomedical research.

Asia-Pacific Research Antibodies Reagents Market Scope

The market is segmented on the basis of type, application, research area, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

By Type

•  Antibodies
  • Antibodies, By Products
    • Primary Antibodies
    • Secondary Antibodies
  • Antibodies, By Source
    • Mouse
    • Rabbit
    • Goat
    • Rat
    • Others
  • Antibodies, Based on Origin
    • Monoclonal Antibodies
    • Polyclonal Antibodies
    • Recombinant Antibodies
• Reagents
  • Reagents, By Type
    • Buffers & Solution
    • Chemiluminescent Reagents
  • Buffers & Solution, By Type
    • PBS (Phosphate Buffered Saline)
    • Blocking Buffers
    • Dilution Buffers
    • Wash Buffers

By Application

• Enzyme-Linked Immunosorbent Assay
• Western Blotting
• Immunohistochemistry
• Flow Cytometry
• Polymerase Chain Reaction
• Others

By Research Area

• Immunology
• Cell & Molecular Biology
• Neuroscience
• Genomics & Proteomics
• Biotechnology & Drug Discovery
• Microbiology
• Others

By End User

• Pharmaceutical and Biopharmaceutical Manufacturers
• Academic And Research Institutes
• Contract Research Organizations (CROs)
• Hospitals & Diagnostic Laboratories
• Others

By Distribution Channel

• Direct Sales
• Third Party Sales
• Others

Asia-Pacific Research Antibodies Reagents Market Regional Analysis

The market is segmented on the basis of type, application, research area, end user and distribution channel.

The countries covered in the market are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and rest of Asia-Pacific.

China is expected to dominate the market due to increasing research activities, government support, and the expansion of biotechnology and pharmaceutical industries.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Asia-Pacific Research Antibodies Reagents Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Asia-Pacific Research Antibodies Reagents Market Leaders Operating in the Market Are:

• Thermo Fisher Scientific (U.S.)
• MilliporeSigma (U.S.)
• Santa Cruz Biotechnology (U.S.)
• Danaher (U.S.)
• Perkinelmer Inc (U.S.)
• F.Hoffmann La Roche Ltd. (Switzerland)
• Rockland Immunochemicals Inc (U.S.)
• Johnsons & Johnsons (U.S.)
• Agilent Technologies Inc. (U.S.)
• Eli Lily and Company (U.S.)
• BD (U.S.)
• Genscript Biotech Corporation (U.S.)

Latest Developments in Asia-Pacific Research Antibodies Reagents Market

• In November 2024, Sigma-Aldrich has announced the winners of its Emerging Biotech Grant Program, which supports innovative biotech startups and researchers. The program aims to foster the development of groundbreaking technologies in life sciences. Winners receive funding, resources, and mentorship to accelerate their research and product development, contributing to advancements in biotechnology
• In September 2024, Sigma-Aldrich has introduced the **Mobius™ ADC** (antibody-drug conjugate) platform, designed to streamline the development and manufacturing of biologics. This advanced platform offers a comprehensive solution for the efficient production of ADCs, enabling faster, more scalable, and cost-effective creation of targeted therapies, enhancing the development of innovative cancer treatments
• In December 2024, Thermo Fisher Scientific has launched CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to support cell therapy development and production. These innovative tools enhance T cell isolation and expansion processes, improving the efficiency and scalability of cell therapies, offering new opportunities for advanced immunotherapies and personalized treatments
• In October 2024, Thermo Fisher Scientific highlighted its expanded biopharma services at CPhI Milan 2024, showcasing innovations designed to support the development and production of complex biologics and cell therapies. These advancements focus on improving the scalability, efficiency, and speed of biopharmaceutical manufacturing, underscoring Thermo Fisher's commitment to accelerating biopharma solutions
• In November 2024, Eli Lilly and Company announced the election of Jon Moeller to its board of directors. Karen Walker resigned from the board, , but will collaborate on digital commercial activities in 2025

SKU-73283